Systemic Immune Inflammation
Systemic Immune Inflammation - Related Videos
03:52
Subcutaneous Injection of Bacterial Antigen to Induce Systemic Inflammation in a Murine Model
0 Views •
2025
This video demonstrates the induction of systemic inflammation in an anesthetized mouse. The injection of mycobacterial antigen-adjuvant depots triggers cytokine release and localized inflammation. Lymphatic vessels open, enabling immune cell entry into lymph nodes and activation of T cells, which release pro-inflammatory cytokines, leading to widespread inflammation.
09:52
A Mouse Model for Pathogen-induced Chronic Inflammation at Local and Systemic Sites
0 Views •
Cited by 15 •
2014
Animal models have proven to be invaluable tools in defining host and pathogen specific mechanisms that contribute to the development of chronic inflammation. Here we describe a mouse model of oral infection with the human pathogen Porphyromonas gingivalis and detail methodologies to assess the progression of inflammation at local and systemic sites.
02:34
Intraperitoneal Injection of Bacterial Lipopolysaccharide in Mice to Study Systemic Immune Responses
0 Views •
2026
Source: Radulovic, K., et al. Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach. J. Vis. Exp. (2018)This video demonstrates a step-by-step procedure for injecting lipopolysaccharide (LPS) into mice intraperitoneally to induce systemic inflammation.
02:49
A Technique to Assess the Immune Response against an Antigen by Inducing Skin Inflammation
0 Views •
2025
This video demonstrates an in vivo technique to assess a test antigen by inducing skin inflammation in a murine model. The test antigen—a hapten in an oil/acetone solution—is topically applied to the skin of the mouse ear, and inflammation of the skin is assessed after an adequate period.
01:38
Inflammation
0 Views •
2019
Overview In response to tissue injury and infection, mast cells initiate inflammation. Mast cells release chemicals that increase the permeability of adjacent blood capillaries and attract additional immune cells to the wound or site of infection. Neutrophils are phagocytic leukocytes that exit the bloodstream and engulf invading microbes. Blood clotting platelets seal the wound and fibers create a scaffold for wound healing. Macrophages engulf aging neutrophils to end the acute inflammatory...
FAQs
Cytokines act as signaling mediators that coordinate immune activity beyond the original site of danger. They can alter blood vessel permeability, helping immune components move into tissues, recruit leukocytes to affected areas, and activate acute-phase responses. These coordinated effects allow the body to respond broadly to infection or injury, but widespread signaling can also increase the risk of tissue and organ disturbance.
Changes in blood vessel permeability help immune components and recruited leukocytes reach tissues involved in the response. This supports host defense and may contribute to tissue repair by bringing inflammatory activity to sites affected by infection or injury. When the response becomes excessive, the same vascular changes can accompany broader inflammation and contribute to clinical signs of disease severity.
The balance between protective and harmful effects depends on the intensity and persistence of immune activation. A controlled response can help defend against infection and support tissue repair, whereas excessive or ongoing inflammation may be associated with fever, organ dysfunction, or chronic disease. This distinction is important because inflammation can be beneficial at one stage and damaging when it remains uncontrolled.
Infection, tissue injury, and other danger signals can initiate systemic immune inflammation when immune cells recognize them. Recognition triggers the release of cytokines and activates downstream processes, including leukocyte recruitment and acute-phase responses. Identifying the initiating context helps clinicians and researchers interpret whether the response is associated with infection, injury, autoimmune disease, or another inflammatory syndrome.
Clinicians consider the extent of immune activation when evaluating how seriously a patient may be affected. The response can involve fever and organ dysfunction, which provide clinically relevant signs alongside other medical findings. Assessing severity helps guide decisions about monitoring and treatment, particularly in conditions where inflammation may progress from a protective response to a harmful systemic process.
Biomarkers provide measurable information that can help clinicians interpret the presence or intensity of inflammatory activity. In medicine, they contribute to assessing disease severity and understanding how the immune response is affecting the patient. Their interpretation is most useful when connected with the clinical context, because systemic inflammation can occur in sepsis, autoimmune disorders, and other inflammatory syndromes.
Understanding the inflammatory response helps clinicians select and evaluate treatments intended to reduce harmful immune activation or modify its activity. Anti-inflammatory and immunomodulatory approaches are relevant when inflammation contributes to disease rather than simply supporting defense and repair. Treatment decisions depend on interpreting the response, its severity, and the associated condition, such as sepsis, autoimmune disease, or an inflammatory syndrome.
These conditions illustrate how broad immune activation can have different clinical contexts. In sepsis, systemic inflammation is relevant to evaluating disease severity and possible organ dysfunction. In autoimmune disorders, it helps frame how immune activity may contribute to ongoing disease. Studying the shared inflammatory processes supports biomarker interpretation, investigation of inflammatory syndromes, and development of targeted immunomodulatory strategies.